Overweight NSCLC patients with the wild-type EGFR status exhibited longer PFS and OS than the underweight patients (4.6 vs. 2.1 months, p = 0.003; 8.9 vs. 4.3 months, p = 0.003, respectively) (Figure 3A,B) Patients who were a normal weight had a longer PFS and OS than those who were underweight (3.5 vs. 2.1 months, p = 0.018; 8.8 vs. 4.3 months, p = 0.003, respectively) (Figure 3A). Here, EGFR is linked to non-small cell lung carcinoma.